TP53 Codon 72 Polymorphism and Breast Cancer Outcomes
Author Information
Author(s): Toyama Tatsuya, Zhang Zhenhuan, Nishio Mariko, Hamaguchi Maho, Kondo Naoto, Iwase Hirotaka, Iwata Hiroji, Takahashi Satoru, Yamashita Hiroko, Fujii Yoshitaka
Primary Institution: Nagoya City University Graduate School of Medical Sciences
Hypothesis
The study investigates whether TP53 codon 72 and MDM2 SNP309 polymorphisms are associated with patient outcomes and the effect of adjuvant systemic therapy in breast cancer.
Conclusion
The Pro/Pro genotype of TP53 codon 72 is an independent prognostic marker in breast cancer patients.
Supporting Evidence
- The Pro/Pro genotype of TP53 codon 72 was associated with poorer disease-free survival.
- Patients receiving adjuvant chemotherapy with the Pro/Pro genotype had significantly worse outcomes.
- MDM2 SNP309 status was not associated with disease-free survival.
Takeaway
This study found that patients with a specific genetic variant (Pro/Pro) of the TP53 gene have worse outcomes after breast cancer treatment, especially if they received chemotherapy.
Methodology
The study analyzed genotypes of TP53 codon 72 and MDM2 SNP309 among 557 breast cancer patients using Cox's proportional hazards regression analysis.
Potential Biases
Potential biases may arise from the retrospective nature of the study and the specific population sampled.
Limitations
The study is retrospective and may not account for all confounding factors.
Participant Demographics
The study involved 557 primary Japanese breast cancer patients.
Statistical Information
P-Value
0.047
Confidence Interval
1.01 to 2.76
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website